New preclinical study shows antibody therapy could offer treatment path for genetic form of ALS
The Swiss Federal Institute of Technology Zurich (ETH) and the University of Zurich are flagging up an impressive number of spin-off establishments in the Life Sciences. In order to perform high quality scientific research, a convenient location with a state-of-the-art facility and the proximity to top-class academic research centers is an asset. The BIO-TECHNOPARK® Schlieren-Zurich provides that environment for biotech companies with a healthy spread of firms at varying stages of business development, which range from recent start-ups to global players like Roche Glycart. Currently the Center has 43 member organizations, 37 of these are life science business start-ups and research groups from the Center for Clinical Research of the University and the University Hospital Zurich.